Japanese Journal of Ophthalmology最新文献

{"title":"Efficacy and safety of ROH-101 (0.15% ganciclovir gel) for cytomegalovirus corneal endotheliitis: an open-label, uncontrolled, phase 3 study in Japan.","authors":"Noriko Koizumi, Dai Miyazaki, Seiichiro Sugita, Chie Sotozono, Tsutomu Inatomi, Hiroshi Goto, Atsushi Shiraishi, Shuichiro Eguchi, Shin-Ichiro Ito, Yuichi Hori, Eiichi Uchio, Takeshi Soma, Takeo Fukuchi, Ken Hayashi, Yusuke Takeuchi, Yoshitsugu Inoue","doi":"10.1007/s10384-025-01168-5","DOIUrl":"10.1007/s10384-025-01168-5","url":null,"abstract":"<p><strong>Purpose: </strong>Cytomegalovirus (CMV) corneal endotheliitis often causes severe visual impairment owing to irreversible corneal endothelial dysfunction. Given the side effects of systemic antiviral therapy, development of an approved topical antiviral agent for CMV corneal endotheliitis is desirable. This study evaluated the efficacy and safety of topical 0.15% GCV gel, ROH-101, in the treatment of CMV corneal endotheliitis in Japanese patients.</p><p><strong>Study design: </strong>Open-label, multicenter, uncontrolled, phase 3 study (jRCT2051210064).</p><p><strong>Methods: </strong>The study was conducted from August 2021 to December 2022, with a 2-week run-in period with 0.1% fluorometholone eye drops alone, a 12-week treatment period with additional ROH-101, and a 24-week post-treatment observation period after discontinuation of ROH-101. The primary endpoint was the proportion of patients achieving a CMV DNA copy number in the aqueous humor of less than 10³ copies/mL at week 12. The clinical findings and safety were assessed over the treatment and post-treatment observation periods.</p><p><strong>Results: </strong>Twelve eyes of 12 patients with PCR-proven CMV corneal endotheliitis were enrolled. Treatment was discontinued in 1 eye owing to an adverse event. The other 11 eyes completed 12 weeks of treatment with 63.6% achieving the primary endpoint. The clinical findings, such as corneal edema, coin-shaped lesions, and anterior chamber inflammation, improved in all 11 eyes and did not worsen in 8 eyes that completed the post-treatment observation period. Endothelial cell density was well maintained, and none of the 11 eyes showed corneal endothelial dysfunction. Mild adverse drug reactions were reported in 3 eyes (8.3%).</p><p><strong>Conclusion: </strong>ROH-101 was a safe and efficacious treatment in Japanese patients diagnosed with CMV corneal endotheliitis.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"296-307"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autologous retina transplantation for refractory highly myopic macular holes: a long-term follow-up.","authors":"Matteo Mario Carlà, Carlos Mateo","doi":"10.1007/s10384-025-01169-4","DOIUrl":"10.1007/s10384-025-01169-4","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate long-term anatomical and functional outcomes of autologous retinal transplantation (ART) in refractory highly myopic macular holes (HMMHs).</p><p><strong>Study design: </strong>Retrospective interventional analysis of 9 eyes with refractory HMMH undergoing ART.</p><p><strong>Methods: </strong>Best-corrected visual acuity (BCVA, Snellen) and optical coherence tomography (OCT) were performed at baseline and each follow-up visit (1, 3, 6, 12, 24 months and the most recent). Preoperatively, we collected minimum linear diameter (MLD) and basal diameter (BD). Post-operatively, central macular thickness (CMT), external limiting membrane (ELM)/ellipsoid zone (EZ) visibility, macular edema (ME) and retinal pigmented epithelium (RPE) atrophy were evaluated.</p><p><strong>Results: </strong>Mean follow-up duration was 46.0 ± 19.6 months. Anatomical success was reached in 7/9 eyes (78%). Median BCVA went from 0.05 (IQR 0.065) at baseline to 0.075 (IQR 0.069) at final follow-up (p = 0.25). Only one eye showed a 2-lines improvement, while BCVA was stable in 4/9 (44%) and worsened in 1 eye (12%). CMT progressively thickened in the first 6 months (177 ± 68 μm), but then decreased to 122 ± 50 μm at final follow-up. Graft merging with the surrounding retina was visible in two eyes, showing partial ELM/EZ recovery and good outcomes. Microcystic-like refractory ME (33%) and long-term RPE atrophy (22%) were reported, while delayed displacement of the graft was seen in one case 6 months after first surgery.</p><p><strong>Conclusion: </strong>ART offered acceptable anatomical success but no visual improvement in our cohort. Lack of graft merging with the surrounding retina, persistent microcystic-like ME, RPE atrophy and hole recurrence were the most frequent shortfalls.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"259-267"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of switching to brolucizumab for neovascular age-related macular degeneration refractory to faricimab.","authors":"Junki Hoshino, Hidetaka Matsumoto, Kosuke Nakamura, Hideo Akiyama","doi":"10.1007/s10384-024-01146-3","DOIUrl":"10.1007/s10384-024-01146-3","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the treatment outcomes of switching to intravitreal brolucizumab (IVBr) for neovascular age-related macular degeneration (nAMD) which did not achieve a dry macula even with 4- or 8-week intervals of intravitreal faricimab (IVF).</p><p><strong>Study design: </strong>Retrospective, interventional case series.</p><p><strong>Methods: </strong>We retrospectively studied 33 eyes of 33 consecutive patients with nAMD who switched to IVBr from IVF, assessing best corrected visual acuity (BCVA), foveal thickness (FT), central choroidal thickness (CCT), and exudative status at baseline and after the switch. For patients that switched 4 weeks after the last IVF (4-week interval group), treatment outcomes were evaluated 4 weeks after the switch. For patients that switched 8 weeks after the last IVF (8-week interval group), treatment outcomes were evaluated after the first 8-week interval following the switch.</p><p><strong>Results: </strong>Thirty-one eyes had completed IVBr treatment up to the evaluation point after the switch. There were no significant changes in BCVA at baseline and after the switch in either group. FT and CCT significantly decreased after the switch compared with baseline in both groups. Moreover, in both groups, exudative changes disappeared or decreased in most cases after the switch. The dry macula rate after the switch was 37.5% and 34.8% in the 4-week and 8-week interval group, respectively. Although brolucizumab-related intraocular inflammation was observed in 3 eyes (9.1%) after the switch, it was ameliorated in response to steroid therapy.</p><p><strong>Conclusion: </strong>Switching to IVBr for nAMD refractory to IVF was generally effective in improving exudative changes in the short term.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"221-229"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between internal limiting membrane preservation and sub-epiretinal membrane space during epiretinal membrane surgery.","authors":"Naoki Horiuchi, Norihiro Nagai, Rihito Ui, Shun-Ichiro Takano, Tetsuya Kawakita, Yutaka Imamura","doi":"10.1007/s10384-024-01145-4","DOIUrl":"10.1007/s10384-024-01145-4","url":null,"abstract":"<p><strong>Purpose: </strong>Internal limiting membrane (ILM) is usually peeled simultaneously with epiretinal membrane (ERM), however, in eyes with glaucoma and ERM, ILM is preserved in order to prevent nerve fiber damage. The aim of this study was to evaluate if a new approach for ERM is effective to keep ILM during surgery.</p><p><strong>Study design: </strong>Retrospective consecutive case series.</p><p><strong>Methods: </strong>ERM was directly grasped with forceps at the site where the scale of submembrane space imaged in OCT was maximum. After the removal of ERM, ILM was stained with brilliant blue G and the area of remaining ILM was graded with 5 patterns. The relationship between ILM preservation and submembrane space was analyzed with ROC curve.</p><p><strong>Results: </strong>Thirty-three eyes of 33 patients undergoing ERM surgery (14 women, mean age: 69.2 years) were enrolled. There were 3 eyes with stage 1, 11 eyes with stage 2, 18 eyes with stage 3, and 1 eye with stage 4. The mean maximum distance between ERM and ILM was 80.5 ± 36.0 μm before surgery. ILM was preserved after initial membrane peeling in 21 of 33 eyes (63.6%). ERM-ILM distance correlated with ILM grading (Spearman rank coefficient: P = 0.03). ROC curve analysis identified cutoff value of ERM-ILM distance for ILM preservation was 66 μm[AUC (95% CI):0.7143 (0.5192-0.9093)].</p><p><strong>Conclusions: </strong>Eyes with larger ERM-ILM distance are likely to show preserved ILM during ERM surgery. ERM-ILM distance appears to be a biomarker of ILM preservation during ERM surgery, which would be useful to minimize neuroretinal damage in eyes with glaucoma and related diseases.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"253-258"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143022390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reliability and validity of pre- and post-operative health-related quality of life in strabismus patients using the Japanese version of the adult strabismus questionnaire (AS-20).","authors":"Shinya Takahashi, Toshiaki Goseki, Shingo Noda, Toru Kawanobe, Eri Ishikawa, Yuichiro Tanaka, Tadahiko Kozawa","doi":"10.1007/s10384-025-01162-x","DOIUrl":"10.1007/s10384-025-01162-x","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to translate the Adult Strabismus-20 (AS-20) questionnaire into Japanese, creating the JAS-20, to assess health-related quality of life (HRQOL) in Japanese strabismus patients for the first time. The HRQOL was compared between patients with strabismus and those with non-strabismus mild eye diseases to evaluate HRQOL changes pre- and post-strabismus surgery.</p><p><strong>Study design: </strong>Prospective cohort study.</p><p><strong>Methods: </strong>The AS-20 was translated into Japanese according to international standards by bilingual health professionals. Participants were recruited from an ophthalmology hospital near Tokyo between May 2022 and August 2023. They included adults over 18 years with strabismus (strabismus group) and those with mild eye diseases without strabismus (control group). Patients with strabismus undergoing surgery were reassessed using the JAS-20 two months after operation. Analyses included comparisons between strabismus and control groups, the presence of diplopia within the strabismus group, and pre- versus post-surgery evaluations.</p><p><strong>Results: </strong>The study included 239 patients: 168 in the strabismus group (114 with diplopia and 54 without diplopia) and 71 in the control group. The strabismus group showed significantly lower JAS-20 scores than the control group, indicating a reduced HRQOL. The patients without diplopia scored lower on the psychosocial scale, whereas those with diplopia scored lower on the functional scale. Despite significant post-surgery HRQOL improvements, strabismus patient scores remained below the control group levels.</p><p><strong>Conclusions: </strong>Strabismus affects HRQOL in Japanese patients; it affects functional aspects in patients with diplopia and psychosocial aspects in those without diplopia. Although surgical intervention significantly enhanced HRQOL, it did not equalize with the control group's HRQOL.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"159-165"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal renal function changes during real-world anti-vascular endothelial growth factor therapy for diabetic macular edema in Japan.","authors":"Ayumi Usui-Ouchi, Shuta Kishishita, Yoshihito Sakanishi, Keitaro Mashimo, Kazunori Tamaki, Moe Matsuzawa, Meiko Kimura, Riyu Ikari, Shuu Morita, Ishin Ninomiya, Toshiro Sakuma, Nobuyuki Ebihara, Shintaro Nakao","doi":"10.1007/s10384-025-01170-x","DOIUrl":"10.1007/s10384-025-01170-x","url":null,"abstract":"<p><strong>Purpose: </strong>This retrospective observational study aimed to investigate the longitudinal changes in renal function and central macular thickness (CMT) and their impact on visual outcomes during anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME).</p><p><strong>Study design: </strong>This study employed a retrospective observational design and analyzed data from treatment-naive patients with DME (62 cases, 100 eyes) receiving anti-VEGF therapy for 36 months. Baseline and follow-up assessments were conducted at 12, 24, and 36 months.</p><p><strong>Methods: </strong>Best corrected visual acuity (BCVA), CMT, number of anti-VEGF injections, HbA1c, serum creatinine (Cre), blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), urinary protein levels, and chronic kidney disease (CKD) stage were measured at each time point.</p><p><strong>Results: </strong>The study population had a mean age of 60.7 ± 12.2 years, with 41 men and 21 women. Over the 36-month period, the mean number of anti-VEGF injections per eye was 5.3 ± 3.3. Maximum CMT significantly decreased at each time point, and final BCVA showed significant improvement (logMAR: - 0.07). HbA1c levels remained stable, BUN and Cre levels increased, and eGFR decreased significantly over time. CKD stage 3+ at 36 months significantly resulted in worse CMT.</p><p><strong>Conclusion: </strong>This retrospective observational study provides valuable insights into the longitudinal changes in renal function and CMT during anti-VEGF therapy for DME. Our findings emphasize the importance of monitoring renal function. This study contributes to our understanding of the complex relationship between renal function, DME, and anti-VEGF therapy, thereby facilitating improved management and outcomes in patients with DME.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"245-252"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Short-term efficacy and safety of PreserFlo MicroShunt in Japanese patients with medically treated primary open-angle glaucoma.","authors":"Haruyuki Suzuki, Rei Sakata, Teruki Yamae, Yukako Ishiyama, Koichiro Sugimoto, Hitomi Saito, Megumi Honjo, Shiroaki Shirato, Makoto Aihara","doi":"10.1007/s10384-024-01159-y","DOIUrl":"10.1007/s10384-024-01159-y","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the efficacy and safety of PreserFlo MicroShunt (PMS) combined with mitomycin C in patients with medically treated primary open-angle glaucoma (POAG).</p><p><strong>Study design: </strong>A retrospective observational study.</p><p><strong>Methods: </strong>The study examined 83 eyes from 83 patients with medically treated glaucoma surgery naive POAG. Preoperative intraocular pressure (IOP) was stratified into three groups: IOP < 15 mmHg (group 1), 15 ≤ IOP < 21 mmHg (group 2), and IOP ≥ 21 mmHg (group 3). IOP levels at week 1, month 1, month 3, and month 6 were evaluated using a linear mixed model, and Kaplan-Meier survival analysis was employed to assess the complete success rate (30% IOP reduction without any medications or interventions) of IOP management. The postoperative complications and interventions were also evaluated.</p><p><strong>Results: </strong>Overall, the mean IOP decreased from 19.2 ± 7.4 mmHg to 11.3 ± 3.1 mmHg, representing a 41% IOP reduction. Especially, in group 1 (mean IOP of 12.8 mmHg), IOP decreased to 10.3 mmHg, achieving a reduction rate of 20%. Overall, 51% (95% confidence interval [CI] 41-62%) of the patients maintained a ≥ 30% IOP reduction (complete success). Minor complications included hypotony (n = 10) and hyphema (n = 30). Needling was performed in 12 eyes, bleb revision in 2, tube re-insertion in 2, and insertion of a second tube in 1.</p><p><strong>Conclusions: </strong>PMS demonstrated significant efficacy in reducing IOP in patients with POAG reagrdless of its preoperative IOP levels. No serious complications affecting the VA were observed.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"287-295"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal changes in parameters associated with tear film stability after instillation of long-acting diquafosol ophthalmic solution in soft contact lens wearers.","authors":"Takashi Itokawa, Takashi Suzuki, Hiroko Iwashita, Yukinobu Okajima, Koji Kakisu, Yuichi Hori","doi":"10.1007/s10384-025-01161-y","DOIUrl":"10.1007/s10384-025-01161-y","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate temporal changes in parameters associated with tear film stability after instillation of long-acting 3% diquafosol ophthalmic solution (DQS LX), which contains polyvinylpyrrolidone.</p><p><strong>Study design: </strong>Prospective crossover study design.</p><p><strong>Methods: </strong>We enrolled 23 eyes of 23 soft contact lens (SCL) wearers (aged 25.3 ± 4.4 years). One-day disposable silicone hydrogel lenses (narafilcon A) were used in this study. DQS LX was instilled without a SCL on the first day. On the other two days, subjects received DQS or DQS LX at 7 h after wearing SCLs. Tear meniscus height (TMH), non-invasive tear break-up time (NIBUT) and ocular surface temperature (OST) were measured before and at 5, 15, 30, 45, 60, 80 and 120 min after instillation.</p><p><strong>Results: </strong>When not wearing SCLs, DQS LX instillation significantly improved TMH for up to 120 min and NIBUT for up to 80 min. When wearing SCLs, DQS and DQS LX instillation significantly increased TMH for up to 45 and 80 min, and NIBUT for up to 15 and 30 min. Compared to DQS, DQS LX administration resulted in a significantly higher TMH at 5, 60 and 80 min, as well as a significantly prolonged NIBUT at 5 and 60 min. OST with and without SCLs also varied depending on the changes in the parameters associated with tear film stability.</p><p><strong>Conclusion: </strong>Compared to DQS, when wearing SCLs, DQS LX was found to increase the amount of tear fluid and improve tear film stability for longer periods.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"308-315"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003482/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143399218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of dry eye associated with autoimmune diseases.","authors":"Ayano Yoshimura, Yuka Hosotani, Nahomi Masuda, Fumi Gomi","doi":"10.1007/s10384-025-01172-9","DOIUrl":"10.1007/s10384-025-01172-9","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the characteristics of dry eye in patients with autoimmune disease.</p><p><strong>Study design: </strong>Retrospective clinical study.</p><p><strong>Methods: </strong>Two hundred and fifty-two eyes from 252 patients (12 men and 240 women, mean age 59.8 ±15.2) with autoimmune disease and dry eye were enrolled. Patients were divided into three groups: primary Sjogren's syndrome, secondary Sjogren's syndrome, and autoimmune disease without Sjogren's syndrome.</p><p><strong>Results: </strong>Among all cases, the mean fluorescein breakup time (FBUT) was 2.7 ± 1.6 s, the van Bijesterveld corneal score was 0.8 ± 0.8, the conjunctival score was 1.5 ± 1.7; and the Schirmer 1 test value was 8.4 ± 8.2 mm. Among all cases, the fluorescein breakup pattern (FBUPs) was tear-deficiency-type dry eye in 43% of eyes (area 11%, line 32%), and short FBUT-type dry eye in 57% (dimple 31%, spot 10%, random 16%). Conjunctival scores showed significant positive correlations with anti-SS-A and anti-SS-B antibody titers in the primary and secondary Sjogren's syndrome groups.</p><p><strong>Conclusion: </strong>More than half of the dry eyes associated with autoimmune diseases were short FBUT-type. Patients with autoimmune disease should be aware of dry eye, even without a diagnosis of Sjogren's syndrome.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"188-195"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143648451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative outcomes of biopsy versus debulking surgery for immunoglobulin G4-related ophthalmic disease: a retrospective comparative study.","authors":"Rikako Iwasaki, Yoshiyuki Kitaguchi, Takeshi Morimoto, Kohji Nishida","doi":"10.1007/s10384-024-01157-0","DOIUrl":"10.1007/s10384-024-01157-0","url":null,"abstract":"<p><strong>Purpose: </strong>To compare the postoperative outcomes of corticosteroid therapy following biopsy with those following debulking surgery in patients with immunoglobulin G4 (IgG4)-related ophthalmic disease (IgG4-ROD).</p><p><strong>Study design: </strong>Retrospective comparative study.</p><p><strong>Methods: </strong>Fifteen patients diagnosed with IgG4-ROD (5 unilateral, 10 bilateral) were retrospectively analyzed. IgG4-ROD was diagnosed based on imaging, histopathology, and blood test results. The biopsy group included patients who underwent resection of minimal tissue for diagnosis, whereas the debulking group included patients who underwent resection of a substantial portion of the mass to decrease the tumor size. Postoperative outcomes after steroid administration, recurrence rates, and changes in lacrimal gland function were compared between the groups.</p><p><strong>Results: </strong>The biopsy and debulking groups included seven and eight patients, respectively. All patients in the biopsy group and 25% of patients in the debulking group required steroid treatment postoperatively (p = 0.0070). Relapse occurred in 71.4% and 12.5% (p = 0.041) and maintenance therapy was required in 57.1% and 12.5% (p = 0.12) patients in the biopsy and debulking groups, respectively. Twelve patients had extraorbital lesions, with one patient receiving corticosteroid treatment for sphenoid bone lesion. Schirmer I test values did not differ preoperatively and postoperatively in either group (biopsy: p = 0.47; debulking: p = 0.72). One patient from the biopsy group developed severe dry eyes, necessitating lacrimal canalicular excision.</p><p><strong>Conclusions: </strong>Debulking surgery effectively reduced the requirement for postoperative steroid administration for recurrent lacrimal gland lesion in patients with IgG4-ROD, indicating its potential as an effective alternative to current standard treatment.</p>","PeriodicalId":14563,"journal":{"name":"Japanese Journal of Ophthalmology","volume":" ","pages":"203-213"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12003488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}